Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59) - Tabular View

Tracking Information

First Received Date ^ICMJE

December 26, 2007

Last Updated Date

June 19, 2009

Start Date ^ICMJE

July 1977

Estimated Primary Completion Date

December 2010 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00591643 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

Official Title ^ICMJE

Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

Brief Summary

The purpose of this study is to find out if your adrenal glands are normal or abnormal. This can be determined by whether or not your adrenal gland concentrates more of a labeled building block of adrenal hormone, norcholesterol. This labeled material had been used as an investigative diagnostic tool for imaging adrenal glands for many years with success in our hands. This is a diagnostic procedure. CT, MRI and Ultrasound can determine the size and presence or absence of tumor but cannot assess the function of the adrenal glands. To determine hormone concentrations from blood samples would involve more invasive catherization.

Detailed Description

To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations.

Study Phase

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Diagnostic, Open Label, Single Group Assignment, Efficacy Study

Condition ^ICMJE

Adrenal Tumors
Adrenal Malignancies
Abnormal Hormonal Secretions
Electrolytes Abnormalities

Intervention ^ICMJE

Other: Imaging, Adrenal acans

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Estimated Enrollment ^ICMJE

100

Estimated Completion Date

December 2010

Estimated Primary Completion Date

December 2010 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Patient with clinical and laboratory suspicions of hypersecretion of adrenal cortical hormones

Exclusion Criteria:

Gender

Both

Ages

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Neeta Pandit-Taskar, MD

pandit-n@mskcc.org

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00591643

Responsible Party

Neeta Pandit-Taskar, MD, Memorial Sloan-Kettering Cancer Center

Study ID Numbers ^ICMJE

77-030

Study Sponsor ^ICMJE

Memorial Sloan-Kettering Cancer Center

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Neeta Pandit-Taskar, MD

Memorial Sloan-Kettering Cancer Center

Information Provided By

Memorial Sloan-Kettering Cancer Center

Verification Date

June 2009

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP